Emmaus Life Sciences (OTCMKTS:EMMA) Releases Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA) posted its quarterly earnings results on Friday. The company reported $0.02 earnings per share for the quarter, Zacks reports. The company had revenue of $6.32 million during the quarter.

Emmaus Life Sciences Price Performance

Shares of EMMA stock opened at $0.01 on Friday. Emmaus Life Sciences has a fifty-two week low of $0.01 and a fifty-two week high of $0.02. The stock’s 50-day moving average is $0.01 and its two-hundred day moving average is $0.01. The firm has a market cap of $807,185.00, a P/E ratio of -0.13 and a beta of 9.37.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.